Tscan Therapeutics Inc (NASDAQ:TCRX) — Market Cap & Net Worth
Market Cap & Net Worth: Tscan Therapeutics Inc (TCRX)
Tscan Therapeutics Inc (NASDAQ:TCRX) has a market capitalization of $54.96 Million ($54.96 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21626 globally and #4763 in its home market, demonstrating a -6.79% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tscan Therapeutics Inc's stock price $0.90 by its total outstanding shares 61074229 (61.07 Million). Review Tscan Therapeutics Inc balance sheet liabilities to assess the company's total debt and financial obligations.
Tscan Therapeutics Inc Market Cap History: 2021 to 2026
Tscan Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $274.83 Million to $54.96 Million (-39.29% CAGR).
Index Memberships
Tscan Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #620 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2077 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.00% | #247 of 263 |
Weight: Tscan Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tscan Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tscan Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.92x
Tscan Therapeutics Inc's market cap is 5.92 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $274.83 Million | $10.14 Million | -$48.62 Million | 27.10x | N/A |
| 2022 | $94.67 Million | $13.54 Million | -$66.22 Million | 6.99x | N/A |
| 2023 | $356.06 Million | $21.05 Million | -$89.22 Million | 16.92x | N/A |
| 2024 | $185.67 Million | $2.82 Million | -$127.50 Million | 65.93x | N/A |
| 2025 | $61.07 Million | $10.32 Million | -$129.77 Million | 5.92x | N/A |
Competitor Companies of TCRX by Market Capitalization
Companies near Tscan Therapeutics Inc in the global market cap rankings as of June 19, 2026.
Key companies related to Tscan Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Tscan Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Tscan Therapeutics Inc's market cap moved from $274.83 Million to $ 54.96 Million, with a yearly change of -39.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $54.96 Million | -10.01% |
| 2025 | $61.07 Million | -67.11% |
| 2024 | $185.67 Million | -47.86% |
| 2023 | $356.06 Million | +276.13% |
| 2022 | $94.67 Million | -65.56% |
| 2021 | $274.83 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Tscan Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $54.96 Million USD |
| MoneyControl | $54.96 Million USD |
| MarketWatch | $54.96 Million USD |
| marketcap.company | $54.96 Million USD |
| Reuters | $54.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tscan Therapeutics Inc
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic… Read more